Non-coding RNAs in cancer diagnosis and therapy

Non-coding RNA Research

Volumn 1, Issue 1, 2016, Pages 69-76

  Rasool, Mahmood ^a   Malik, Arif ^b   Zahid, Sara ^b   Basit Ashraf, Muhammad Abdul ^b   Qazi, Mahmood Husain ^b   Asif, Muhammad ^c   Zaheer, Ahmad ^d   Arshad, Muhammad ^d   Raza, Amir ^d   Jamal, Mohammad Sarwar ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF LAHORE   (Pakistan)

^c BALOCHISTAN UNIVERSITY OF INFORMATION TECHNOLOGY   (Pakistan)

^d NATIONAL INSTITUTE FOR BIOTECHNOLOGY AND GENETIC ENGINEERING NIBGE   (Pakistan)

Author keywords

Genetic expression; Metastasis; microRNA; Oncogene; Oncomirs; Transcription

Indexed keywords

ANTIINFECTIVE AGENT; AZACITIDINE; BIOLOGICAL MARKER; COMPLEMENTARY RNA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DECITABINE; ENOXACIN; GROWTH ARREST SPECIFIC PROTEIN 5; GROWTH ARREST SPECIFIC PROTEIN 6; HOX PROTEIN; K RAS PROTEIN; LOCKED NUCLEIC ACID; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 155; MICRORNA 15A; MICRORNA 16; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN BCL 2; RAS PROTEIN; SMALL UNTRANSLATED RNA; TAR RNA BINDING PROTEIN 2; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

BASE PAIRING; BIOINFORMATICS; BREAST CANCER; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CPG ISLAND; DNA MODIFICATION; DRUG TARGETING; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; GENETIC DATABASE; HISTONE MODIFICATION; HUMAN; METASTASIS; MICROARRAY ANALYSIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; ONCOGENE MYC; ONCOGENE RAS; PROSTATE CANCER; PROTEOMICS; PSEUDOGENE; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR INVASION; UTERINE CERVIX CANCER;

EID: 85017241430     PISSN: 24680540     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncrna.2016.11.001     Document Type: Review

References (53)

1. [1] Mendell, J.T., Olson, E.N., MicroRNAs in stress signaling and human disease. Cell 148 (2012), 1172–1187.
2. [2] Esteller, M., Non-coding RNAs in human disease. Nat. Rev. Genet. 12 (2011), 861–874.
3. [3] Spizzo, R., Almeida, M.I., Colombatti, A., et al. Long non-coding RNAs and cancer: a new frontier of translational research?. Oncogene 31 (2012), 4577–4587.
4. [4] Pennisi, E., Genomics. ENCODE project writes eulogy for junk DNA. Science 337 (2012), 1159–1161.
5. [5] Dunham, I., An integrated encyclopedia of DNA elements in the human genome. Nature 489 (2012), 57–74.
6. [6] Djebali, S., Davis, C.A., Merkel, A., et al. Landscape of transcription in human cells. Nature 489:7414 (2012), 101–108.
7. [7] Fabian, M.R., Sonenberg, N., Filipowicz, W., Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 79 (2010), 351–379.
8. [8] Garzon, R., Marcucci, G., Croce, C.M., Targeting microRNAs in cancer: rationale, within cell-cycle promoters. Nat. Genet. 43 (2011), 621–629.
9. [9] Thorsen, S.B., Obad, S., Jensenet, N.F., et al. The therapeutic potential of microRNAs in cancer. Cancer J. 18 (2012), 275–284.
10. [10] Van Rooij, E., Olson, E.N., MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 11 (2012), 860–872.
11. [11] Wahlestedt, C., Targeting long non-coding RNA to therapeutically upregulate gene strategies and challenges. Nat. Rev. Drug Discov. 9 (2012), 775–789.
12. [12] Fabbri, M., MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), E2110–E2116.
13. [13] Vickers, K.C., Palmisano, B.T., Shoucri, B.M., et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 13 (2011), 423–433.
14. [14] Kasinski, A.L., Slack, F.J., Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 11 (2011), 849–864.
15. [15] Pencheva, N., Tavazoie, S.F., Control of metastatic progression by microRNA regulatory networks. Nat. Cell Biol. 15 (2013), 546–554.
16. [16] Png, K.J., Halberg, N., Yoshida, M., M, et al. microRNA regular that mediates endothelial recruitment and metastasis by cancer cells. Nature 481 (2012), 190–194.
17. [17] Song, S.J., MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 154 (2013), 311–324.
18. [18] Uhlmann, S., Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol. Syst. Biol., 8, 2012, 570.
19. [19] Almeida, M.I., Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells. Gastroenterology, 142, 2012 886–896e9.
20. [20] Melo, S., et al. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 4394–4399.
21. [21] Bader, A.G., Brown, D., Stoudemire, J., et al. Developing therapeutic microRNAs for cancer. Gene Ther. 18 (2011), 1121–1126.
22. [22] Tivnan, A., Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticle. PLoS ONE, 7, 2012, e38129.
23. [23] Trang, P., et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 19 (2011), 1116–1122.
24. [24] Chen, L., Tumor-specific expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and -independent pathways. Mol. Ther. 19 (2011), 1521–1528.
25. [25] Bader, A.G., miR-34-a microRNA replacement therapy is headed to the clinic Front. Genet, 3, 2012, 120.
26. [26] Janssen, H.L., et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368 (2013), 1685–1694.
27. [27] Zhang, Y., et al. LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood 120 (2012), 1678–1686 (km).
28. [28] Kluiver, J., et al. Rapid generation of microRNA sponges for microRNA inhibition. PLoS ONE, 7, 2012, e29275.
29. [29] Dvinge, H., The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 497 (2013), 378–382.
30. [30] Lehmann, S.M., et al. An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat. Neurosci. 15 (2012), 827–835.
31. [31] Jiang, K., Biotech comes to its ‘antisenses’ after hard-won drug approval. Nat. Med., 19, 2013, 252.
32. [32] Ding, L., Hu, X.M., Wu, H., et al. Combined transfection of Bcl-2 siRNA and miR-15a oligonucleotides enhanced methotrexate-induced apoptosis in Raji cells. Can. Bio Med. 10 (2013), 16–21.
33. [33] Hu, X., Jung, E.J., Calin, G.A., The effect of Bcl-2 siRNA combined with miR-15a oligonucleotides on the growth of Raji cells. Med. Oncol., 30, 2013, 430.
34. [34] Bockhorn, J., Stoudemire, J., Lammers, P., MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat. Commun., 4, 2013, 1393.
35. [35] Memczal, S., Poliseno, L., Tay, Y., Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495 (2013), 333–338.
36. [36] Ling, H., Jung, E.J., Calin, G.A., CCAT2, a Novel Non-coding RNA Mapping to 8q24. 2013.
37. [37] Salmena, L., Poliseno, L., Tay, Y., A ceRNA hypothesis: the miR-15a oligonucleotides enhanced methotrexate-induced apoptosis in Raji cells. Cancer 154 (2013), 311–324.
38. [38] Poliseno, L., Pencheva, N., Tavazoie, S.F., A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465 (2010), 1033–1038.
39. [39] Hung, T., Li, C.H., Chen, Y., Extensive and coordinated transcription of noncoding RNAs expression. Nat. Rev. Drug Discov. 12 (2013), 433–446.
40. [40] Wheeler, T.M., Kino, T., Hurt, D.E., et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488 (2012), 111–115.
41. [41] Gutschner, T., The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 73 (2013), 1180–1189.
42. [42] Kino, T., Hurt, D.E., Ichijo, T., et al. Noncoding RNA Gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci. Signal, 3, 2010, 8.
43. [43] Rusk, N., AntagoNATs boost gene expression. Nat. Methods, 9, 2012, 437.
44. [44] Modarresi, F., et al. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat. Biotech. 30 (2012), 453–459.
45. [45] Flemming, A., Regulatory watch: pioneering gene therapy on brink of approval. Nat. Rev. Drug Discov., 11, 2012, 664.
46. [46] Gruber, K., Europe gives gene therapy the green light. Lancet, 380, 2012, e10.
47. [47] Hansen, T.B., Natural RNA circles function as efficient microRNA sponges. Nature 495 (2013), 384–388.
48. [48] Guttman, M., Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458 (2009), 223–227.
49. [49] Lai, F., et al. Activating RNAs associate with Mediator to enhance chromatin architecture and transcription. Nature 494 (2013), 497–501.
50. [50] Redis, R.S., Calin, S., Yang, Y., et al. Cell-to-cell miRNA transfer: from body homeostasis to therapy. Pharmacol. Ther. 136 (2012), 169–174.
51. [51] Yang, M., et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol. Cancer, 10, 2011, 117.
52. [52] Yang, S., et al. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene 32 (2012), 4294–4303.
53. [53] Crawford, E.D., Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J. Urol. 188 (2012), 1726–1731.